What is the projected market valuation for the Postoperative Nausea and Vomiting Market in 2035?

The projected market valuation for the Postoperative Nausea and Vomiting Market in 2035 is 6.503 USD Billion. Read More

What was the overall market valuation for the Postoperative Nausea and Vomiting Market in 2024?

The overall market valuation for the Postoperative Nausea and Vomiting Market in 2024 was 4.251 USD Billion. Read More

What is the expected CAGR for the Postoperative Nausea and Vomiting Market from 2025 to 2035?

The expected CAGR for the Postoperative Nausea and Vomiting Market during the forecast period 2025 - 2035 is 3.94%. Read More

Which companies are considered key players in the Postoperative Nausea and Vomiting Market?

Key players in the Postoperative Nausea and Vomiting Market include Fresenius Kabi, Baxter International, GlaxoSmithKline, Merck & Co., AstraZeneca, Novartis, Teva Pharmaceutical Industries, Eisai Co., Ltd., and Hikma Pharmaceuticals. Read More

What are the projected values for Pharmacological Treatment in the Postoperative Nausea and Vomiting Market by 2035?

The projected value for Pharmacological Treatment in the Postoperative Nausea and Vomiting Market is expected to reach 3.125 USD Billion by 2035. Read More

How does the market for Non-Pharmacological Treatment compare to Combination Therapy in 2035?

By 2035, the market for Non-Pharmacological Treatment is projected to be 1.875 USD Billion, while Combination Therapy is expected to reach 1.503 USD Billion. Read More

What is the anticipated market size for 5-HT3 Antagonists in 2035?

The anticipated market size for 5-HT3 Antagonists in 2035 is projected to be 1.925 USD Billion. Read More

What are the expected values for the Administration Route segment by 2035?

By 2035, the expected values for the Administration Route segment are 1.925 USD Billion for Oral, 2.325 USD Billion for Intravenous, and 2.253 USD Billion for Rectal. Read More

What is the projected market size for Adult Patients in the Postoperative Nausea and Vomiting Market by 2035?

The projected market size for Adult Patients in the Postoperative Nausea and Vomiting Market is expected to reach 3.2515 USD Billion by 2035. Read More

How do the market values for Geriatric Patients compare to Pediatric Patients in 2035?

In 2035, the market value for Geriatric Patients is projected to be 2.6012 USD Billion, compared to 0.6503 USD Billion for Pediatric Patients. Read More

Postoperative Nausea Vomiting Market

Postoperative Nausea and Vomiting Market Research Report: Size, Share, Trend Analysis By Types of Treatment (Pharmacological Treatment, Non-Pharmacological Treatment, Combination Therapy), By Medication Class (5-HT3 Antagonists, Dopamine Antagonists, Antihistamines, Corticosteroids), By Administration Route (Oral, Intravenous, Rectal), By Patient Demographics (Pediatric Patients, Adult Patients, Geriatric Patients) and By Region (North America, Europe, South America, Asia Pacific, Middle East and Africa) - Growth Outlook & Industry Forecast 2025 To 2035

Forecast Period

2025 - 2035

CAGR

3.94%

2024 Market Size

$ 4.25 Billion

2035 Market Size

$ 6.5 Billion

Healthcare ● Updated April 2026 Report ID: MRFR/HC/41643-HCR | Pages: 200 | Author: Rahul Gotadki

Summary Table of Contents Segmentation Download PDF

SECTION I: EXECUTIVE SUMMARY AND KEY HIGHLIGHTS |
1. 1.1 EXECUTIVE SUMMARY | |
  1. 1.1.1 Market Overview | |
  2. 1.1.2 Key Findings | |
  3. 1.1.3 Market Segmentation | |
  4. 1.1.4 Competitive Landscape | |
  5. 1.1.5 Challenges and Opportunities | |
  6. 1.1.6 Future Outlook 2
SECTION II: SCOPING, METHODOLOGY AND MARKET STRUCTURE |
1. 2.1 MARKET INTRODUCTION | |
  1. 2.1.1 Definition | |
  2. 2.1.2 Scope of the study | | |
    1. 2.1.2.1 Research Objective | | |
    2. 2.1.2.2 Assumption | | |
    3. 2.1.2.3 Limitations |
2. 2.2 RESEARCH METHODOLOGY | |
  1. 2.2.1 Overview | |
  2. 2.2.2 Data Mining | |
  3. 2.2.3 Secondary Research | |
  4. 2.2.4 Primary Research | | |
    1. 2.2.4.1 Primary Interviews and Information Gathering Process | | |
    2. 2.2.4.2 Breakdown of Primary Respondents | |
  5. 2.2.5 Forecasting Model | |
  6. 2.2.6 Market Size Estimation | | |
    1. 2.2.6.1 Bottom-Up Approach | | |
    2. 2.2.6.2 Top-Down Approach | |
  7. 2.2.7 Data Triangulation | |
  8. 2.2.8 Validation 3
SECTION III: QUALITATIVE ANALYSIS |
1. 3.1 MARKET DYNAMICS | |
  1. 3.1.1 Overview | |
  2. 3.1.2 Drivers | |
  3. 3.1.3 Restraints | |
  4. 3.1.4 Opportunities |
2. 3.2 MARKET FACTOR ANALYSIS | |
  1. 3.2.1 Value chain Analysis | |
  2. 3.2.2 Porter's Five Forces Analysis | | |
    1. 3.2.2.1 Bargaining Power of Suppliers | | |
    2. 3.2.2.2 Bargaining Power of Buyers | | |
    3. 3.2.2.3 Threat of New Entrants | | |
    4. 3.2.2.4 Threat of Substitutes | | |
    5. 3.2.2.5 Intensity of Rivalry | |
  3. 3.2.3 COVID-19 Impact Analysis | | |
    1. 3.2.3.1 Market Impact Analysis | | |
    2. 3.2.3.2 Regional Impact | | |
    3. 3.2.3.3 Opportunity and Threat Analysis 4
SECTION IV: QUANTITATIVE ANALYSIS |
1. 4.1 Healthcare, BY Type of Treatment (USD Billion) | |
  1. 4.1.1 Pharmacological Treatment | |
  2. 4.1.2 Non-Pharmacological Treatment | |
  3. 4.1.3 Combination Therapy |
2. 4.2 Healthcare, BY Medication Class (USD Billion) | |
  1. 4.2.1 5-HT3 Antagonists | |
  2. 4.2.2 Dopamine Antagonists | |
  3. 4.2.3 Antihistamines | |
  4. 4.2.4 Corticosteroids |
3. 4.3 Healthcare, BY Administration Route (USD Billion) | |
  1. 4.3.1 Oral | |
  2. 4.3.2 Intravenous | |
  3. 4.3.3 Rectal |
4. 4.4 Healthcare, BY Patient Demographics (USD Billion) | |
  1. 4.4.1 Pediatric Patients | |
  2. 4.4.2 Adult Patients | |
  3. 4.4.3 Geriatric Patients |
5. 4.5 Healthcare, BY Region (USD Billion) | |
  1. 4.5.1 North America | | |
    1. 4.5.1.1 US | | |
    2. 4.5.1.2 Canada | |
  2. 4.5.2 Europe | | |
    1. 4.5.2.1 Germany | | |
    2. 4.5.2.2 UK | | |
    3. 4.5.2.3 France | | |
    4. 4.5.2.4 Russia | | |
    5. 4.5.2.5 Italy | | |
    6. 4.5.2.6 Spain | | |
    7. 4.5.2.7 Rest of Europe | |
  3. 4.5.3 APAC | | |
    1. 4.5.3.1 China | | |
    2. 4.5.3.2 India | | |
    3. 4.5.3.3 Japan | | |
    4. 4.5.3.4 South Korea | | |
    5. 4.5.3.5 Malaysia | | |
    6. 4.5.3.6 Thailand | | |
    7. 4.5.3.7 Indonesia | | |
    8. 4.5.3.8 Rest of APAC | |
  4. 4.5.4 South America | | |
    1. 4.5.4.1 Brazil | | |
    2. 4.5.4.2 Mexico | | |
    3. 4.5.4.3 Argentina | | |
    4. 4.5.4.4 Rest of South America | |
  5. 4.5.5 MEA | | |
    1. 4.5.5.1 GCC Countries | | |
    2. 4.5.5.2 South Africa | | |
    3. 4.5.5.3 Rest of MEA 5
SECTION V: COMPETITIVE ANALYSIS |
1. 5.1 Competitive Landscape | |
  1. 5.1.1 Overview | |
  2. 5.1.2 Competitive Analysis | |
  3. 5.1.3 Market share Analysis | |
  4. 5.1.4 Major Growth Strategy in the Healthcare | |
  5. 5.1.5 Competitive Benchmarking | |
  6. 5.1.6 Leading Players in Terms of Number of Developments in the Healthcare | |
  7. 5.1.7 Key developments and growth strategies | | |
    1. 5.1.7.1 New Product Launch/Service Deployment | | |
    2. 5.1.7.2 Merger & Acquisitions | | |
    3. 5.1.7.3 Joint Ventures | |
  8. 5.1.8 Major Players Financial Matrix | | |
    1. 5.1.8.1 Sales and Operating Income | | |
    2. 5.1.8.2 Major Players R&D Expenditure. 2023 |
2. 5.2 Company Profiles | |
  1. 5.2.1 Fresenius Kabi (DE) | | |
    1. 5.2.1.1 Financial Overview | | |
    2. 5.2.1.2 Products Offered | | |
    3. 5.2.1.3 Key Developments | | |
    4. 5.2.1.4 SWOT Analysis | | |
    5. 5.2.1.5 Key Strategies | |
  2. 5.2.2 Baxter International (US) | | |
    1. 5.2.2.1 Financial Overview | | |
    2. 5.2.2.2 Products Offered | | |
    3. 5.2.2.3 Key Developments | | |
    4. 5.2.2.4 SWOT Analysis | | |
    5. 5.2.2.5 Key Strategies | |
  3. 5.2.3 GlaxoSmithKline (GB) | | |
    1. 5.2.3.1 Financial Overview | | |
    2. 5.2.3.2 Products Offered | | |
    3. 5.2.3.3 Key Developments | | |
    4. 5.2.3.4 SWOT Analysis | | |
    5. 5.2.3.5 Key Strategies | |
  4. 5.2.4 Merck & Co. (US) | | |
    1. 5.2.4.1 Financial Overview | | |
    2. 5.2.4.2 Products Offered | | |
    3. 5.2.4.3 Key Developments | | |
    4. 5.2.4.4 SWOT Analysis | | |
    5. 5.2.4.5 Key Strategies | |
  5. 5.2.5 AstraZeneca (GB) | | |
    1. 5.2.5.1 Financial Overview | | |
    2. 5.2.5.2 Products Offered | | |
    3. 5.2.5.3 Key Developments | | |
    4. 5.2.5.4 SWOT Analysis | | |
    5. 5.2.5.5 Key Strategies | |
  6. 5.2.6 Novartis (CH) | | |
    1. 5.2.6.1 Financial Overview | | |
    2. 5.2.6.2 Products Offered | | |
    3. 5.2.6.3 Key Developments | | |
    4. 5.2.6.4 SWOT Analysis | | |
    5. 5.2.6.5 Key Strategies | |
  7. 5.2.7 Teva Pharmaceutical Industries (IL) | | |
    1. 5.2.7.1 Financial Overview | | |
    2. 5.2.7.2 Products Offered | | |
    3. 5.2.7.3 Key Developments | | |
    4. 5.2.7.4 SWOT Analysis | | |
    5. 5.2.7.5 Key Strategies | |
  8. 5.2.8 Eisai Co., Ltd. (JP) | | |
    1. 5.2.8.1 Financial Overview | | |
    2. 5.2.8.2 Products Offered | | |
    3. 5.2.8.3 Key Developments | | |
    4. 5.2.8.4 SWOT Analysis | | |
    5. 5.2.8.5 Key Strategies | |
  9. 5.2.9 Hikma Pharmaceuticals (GB) | | |
    1. 5.2.9.1 Financial Overview | | |
    2. 5.2.9.2 Products Offered | | |
    3. 5.2.9.3 Key Developments | | |
    4. 5.2.9.4 SWOT Analysis | | |
    5. 5.2.9.5 Key Strategies |
3. 5.3 Appendix | |
  1. 5.3.1 References | |
  2. 5.3.2 Related Reports 6 LIST OF FIGURES |
4. 6.1 MARKET SYNOPSIS |
5. 6.2 NORTH AMERICA MARKET ANALYSIS |
6. 6.3 US MARKET ANALYSIS BY TYPE OF TREATMENT |
7. 6.4 US MARKET ANALYSIS BY MEDICATION CLASS |
8. 6.5 US MARKET ANALYSIS BY ADMINISTRATION ROUTE |
9. 6.6 US MARKET ANALYSIS BY PATIENT DEMOGRAPHICS |
10. 6.7 CANADA MARKET ANALYSIS BY TYPE OF TREATMENT |
11. 6.8 CANADA MARKET ANALYSIS BY MEDICATION CLASS |
12. 6.9 CANADA MARKET ANALYSIS BY ADMINISTRATION ROUTE |
13. 6.10 CANADA MARKET ANALYSIS BY PATIENT DEMOGRAPHICS |
14. 6.11 EUROPE MARKET ANALYSIS |
15. 6.12 GERMANY MARKET ANALYSIS BY TYPE OF TREATMENT |
16. 6.13 GERMANY MARKET ANALYSIS BY MEDICATION CLASS |
17. 6.14 GERMANY MARKET ANALYSIS BY ADMINISTRATION ROUTE |
18. 6.15 GERMANY MARKET ANALYSIS BY PATIENT DEMOGRAPHICS |
19. 6.16 UK MARKET ANALYSIS BY TYPE OF TREATMENT |
20. 6.17 UK MARKET ANALYSIS BY MEDICATION CLASS |
21. 6.18 UK MARKET ANALYSIS BY ADMINISTRATION ROUTE |
22. 6.19 UK MARKET ANALYSIS BY PATIENT DEMOGRAPHICS |
23. 6.20 FRANCE MARKET ANALYSIS BY TYPE OF TREATMENT |
24. 6.21 FRANCE MARKET ANALYSIS BY MEDICATION CLASS |
25. 6.22 FRANCE MARKET ANALYSIS BY ADMINISTRATION ROUTE |
26. 6.23 FRANCE MARKET ANALYSIS BY PATIENT DEMOGRAPHICS |
27. 6.24 RUSSIA MARKET ANALYSIS BY TYPE OF TREATMENT |
28. 6.25 RUSSIA MARKET ANALYSIS BY MEDICATION CLASS |
29. 6.26 RUSSIA MARKET ANALYSIS BY ADMINISTRATION ROUTE |
30. 6.27 RUSSIA MARKET ANALYSIS BY PATIENT DEMOGRAPHICS |
31. 6.28 ITALY MARKET ANALYSIS BY TYPE OF TREATMENT |
32. 6.29 ITALY MARKET ANALYSIS BY MEDICATION CLASS |
33. 6.30 ITALY MARKET ANALYSIS BY ADMINISTRATION ROUTE |
34. 6.31 ITALY MARKET ANALYSIS BY PATIENT DEMOGRAPHICS |
35. 6.32 SPAIN MARKET ANALYSIS BY TYPE OF TREATMENT |
36. 6.33 SPAIN MARKET ANALYSIS BY MEDICATION CLASS |
37. 6.34 SPAIN MARKET ANALYSIS BY ADMINISTRATION ROUTE |
38. 6.35 SPAIN MARKET ANALYSIS BY PATIENT DEMOGRAPHICS |
39. 6.36 REST OF EUROPE MARKET ANALYSIS BY TYPE OF TREATMENT |
40. 6.37 REST OF EUROPE MARKET ANALYSIS BY MEDICATION CLASS |
41. 6.38 REST OF EUROPE MARKET ANALYSIS BY ADMINISTRATION ROUTE |
42. 6.39 REST OF EUROPE MARKET ANALYSIS BY PATIENT DEMOGRAPHICS |
43. 6.40 APAC MARKET ANALYSIS |
44. 6.41 CHINA MARKET ANALYSIS BY TYPE OF TREATMENT |
45. 6.42 CHINA MARKET ANALYSIS BY MEDICATION CLASS |
46. 6.43 CHINA MARKET ANALYSIS BY ADMINISTRATION ROUTE |
47. 6.44 CHINA MARKET ANALYSIS BY PATIENT DEMOGRAPHICS |
48. 6.45 INDIA MARKET ANALYSIS BY TYPE OF TREATMENT |
49. 6.46 INDIA MARKET ANALYSIS BY MEDICATION CLASS |
50. 6.47 INDIA MARKET ANALYSIS BY ADMINISTRATION ROUTE |
51. 6.48 INDIA MARKET ANALYSIS BY PATIENT DEMOGRAPHICS |
52. 6.49 JAPAN MARKET ANALYSIS BY TYPE OF TREATMENT |
53. 6.50 JAPAN MARKET ANALYSIS BY MEDICATION CLASS |
54. 6.51 JAPAN MARKET ANALYSIS BY ADMINISTRATION ROUTE |
55. 6.52 JAPAN MARKET ANALYSIS BY PATIENT DEMOGRAPHICS |
56. 6.53 SOUTH KOREA MARKET ANALYSIS BY TYPE OF TREATMENT |
57. 6.54 SOUTH KOREA MARKET ANALYSIS BY MEDICATION CLASS |
58. 6.55 SOUTH KOREA MARKET ANALYSIS BY ADMINISTRATION ROUTE |
59. 6.56 SOUTH KOREA MARKET ANALYSIS BY PATIENT DEMOGRAPHICS |
60. 6.57 MALAYSIA MARKET ANALYSIS BY TYPE OF TREATMENT |
61. 6.58 MALAYSIA MARKET ANALYSIS BY MEDICATION CLASS |
62. 6.59 MALAYSIA MARKET ANALYSIS BY ADMINISTRATION ROUTE |
63. 6.60 MALAYSIA MARKET ANALYSIS BY PATIENT DEMOGRAPHICS |
64. 6.61 THAILAND MARKET ANALYSIS BY TYPE OF TREATMENT |
65. 6.62 THAILAND MARKET ANALYSIS BY MEDICATION CLASS |
66. 6.63 THAILAND MARKET ANALYSIS BY ADMINISTRATION ROUTE |
67. 6.64 THAILAND MARKET ANALYSIS BY PATIENT DEMOGRAPHICS |
68. 6.65 INDONESIA MARKET ANALYSIS BY TYPE OF TREATMENT |
69. 6.66 INDONESIA MARKET ANALYSIS BY MEDICATION CLASS |
70. 6.67 INDONESIA MARKET ANALYSIS BY ADMINISTRATION ROUTE |
71. 6.68 INDONESIA MARKET ANALYSIS BY PATIENT DEMOGRAPHICS |
72. 6.69 REST OF APAC MARKET ANALYSIS BY TYPE OF TREATMENT |
73. 6.70 REST OF APAC MARKET ANALYSIS BY MEDICATION CLASS |
74. 6.71 REST OF APAC MARKET ANALYSIS BY ADMINISTRATION ROUTE |
75. 6.72 REST OF APAC MARKET ANALYSIS BY PATIENT DEMOGRAPHICS |
76. 6.73 SOUTH AMERICA MARKET ANALYSIS |
77. 6.74 BRAZIL MARKET ANALYSIS BY TYPE OF TREATMENT |
78. 6.75 BRAZIL MARKET ANALYSIS BY MEDICATION CLASS |
79. 6.76 BRAZIL MARKET ANALYSIS BY ADMINISTRATION ROUTE |
80. 6.77 BRAZIL MARKET ANALYSIS BY PATIENT DEMOGRAPHICS |
81. 6.78 MEXICO MARKET ANALYSIS BY TYPE OF TREATMENT |
82. 6.79 MEXICO MARKET ANALYSIS BY MEDICATION CLASS |
83. 6.80 MEXICO MARKET ANALYSIS BY ADMINISTRATION ROUTE |
84. 6.81 MEXICO MARKET ANALYSIS BY PATIENT DEMOGRAPHICS |
85. 6.82 ARGENTINA MARKET ANALYSIS BY TYPE OF TREATMENT |
86. 6.83 ARGENTINA MARKET ANALYSIS BY MEDICATION CLASS |
87. 6.84 ARGENTINA MARKET ANALYSIS BY ADMINISTRATION ROUTE |
88. 6.85 ARGENTINA MARKET ANALYSIS BY PATIENT DEMOGRAPHICS |
89. 6.86 REST OF SOUTH AMERICA MARKET ANALYSIS BY TYPE OF TREATMENT |
90. 6.87 REST OF SOUTH AMERICA MARKET ANALYSIS BY MEDICATION CLASS |
91. 6.88 REST OF SOUTH AMERICA MARKET ANALYSIS BY ADMINISTRATION ROUTE |
92. 6.89 REST OF SOUTH AMERICA MARKET ANALYSIS BY PATIENT DEMOGRAPHICS |
93. 6.90 MEA MARKET ANALYSIS |
94. 6.91 GCC COUNTRIES MARKET ANALYSIS BY TYPE OF TREATMENT |
95. 6.92 GCC COUNTRIES MARKET ANALYSIS BY MEDICATION CLASS |
96. 6.93 GCC COUNTRIES MARKET ANALYSIS BY ADMINISTRATION ROUTE |
97. 6.94 GCC COUNTRIES MARKET ANALYSIS BY PATIENT DEMOGRAPHICS |
98. 6.95 SOUTH AFRICA MARKET ANALYSIS BY TYPE OF TREATMENT |
99. 6.96 SOUTH AFRICA MARKET ANALYSIS BY MEDICATION CLASS |
100. 6.97 SOUTH AFRICA MARKET ANALYSIS BY ADMINISTRATION ROUTE |
101. 6.98 SOUTH AFRICA MARKET ANALYSIS BY PATIENT DEMOGRAPHICS |
102. 6.99 REST OF MEA MARKET ANALYSIS BY TYPE OF TREATMENT |
103. 6.100 REST OF MEA MARKET ANALYSIS BY MEDICATION CLASS |
104. 6.101 REST OF MEA MARKET ANALYSIS BY ADMINISTRATION ROUTE |
105. 6.102 REST OF MEA MARKET ANALYSIS BY PATIENT DEMOGRAPHICS |
106. 6.103 KEY BUYING CRITERIA OF HEALTHCARE |
107. 6.104 RESEARCH PROCESS OF MRFR |
108. 6.105 DRO ANALYSIS OF HEALTHCARE |
109. 6.106 DRIVERS IMPACT ANALYSIS: HEALTHCARE |
110. 6.107 RESTRAINTS IMPACT ANALYSIS: HEALTHCARE |
111. 6.108 SUPPLY / VALUE CHAIN: HEALTHCARE |
112. 6.109 HEALTHCARE, BY TYPE OF TREATMENT, 2024 (% SHARE) |
113. 6.110 HEALTHCARE, BY TYPE OF TREATMENT, 2024 TO 2035 (USD Billion) |
114. 6.111 HEALTHCARE, BY MEDICATION CLASS, 2024 (% SHARE) |
115. 6.112 HEALTHCARE, BY MEDICATION CLASS, 2024 TO 2035 (USD Billion) |
116. 6.113 HEALTHCARE, BY ADMINISTRATION ROUTE, 2024 (% SHARE) |
117. 6.114 HEALTHCARE, BY ADMINISTRATION ROUTE, 2024 TO 2035 (USD Billion) |
118. 6.115 HEALTHCARE, BY PATIENT DEMOGRAPHICS, 2024 (% SHARE) |
119. 6.116 HEALTHCARE, BY PATIENT DEMOGRAPHICS, 2024 TO 2035 (USD Billion) |
120. 6.117 BENCHMARKING OF MAJOR COMPETITORS 7 LIST OF TABLES |
121. 7.1 LIST OF ASSUMPTIONS | |
  1. 7.1.1 |
122. 7.2 North America MARKET SIZE ESTIMATES; FORECAST | |
  1. 7.2.1 BY TYPE OF TREATMENT, 2025-2035 (USD Billion) | |
  2. 7.2.2 BY MEDICATION CLASS, 2025-2035 (USD Billion) | |
  3. 7.2.3 BY ADMINISTRATION ROUTE, 2025-2035 (USD Billion) | |
  4. 7.2.4 BY PATIENT DEMOGRAPHICS, 2025-2035 (USD Billion) |
123. 7.3 US MARKET SIZE ESTIMATES; FORECAST | |
  1. 7.3.1 BY TYPE OF TREATMENT, 2025-2035 (USD Billion) | |
  2. 7.3.2 BY MEDICATION CLASS, 2025-2035 (USD Billion) | |
  3. 7.3.3 BY ADMINISTRATION ROUTE, 2025-2035 (USD Billion) | |
  4. 7.3.4 BY PATIENT DEMOGRAPHICS, 2025-2035 (USD Billion) |
124. 7.4 Canada MARKET SIZE ESTIMATES; FORECAST | |
  1. 7.4.1 BY TYPE OF TREATMENT, 2025-2035 (USD Billion) | |
  2. 7.4.2 BY MEDICATION CLASS, 2025-2035 (USD Billion) | |
  3. 7.4.3 BY ADMINISTRATION ROUTE, 2025-2035 (USD Billion) | |
  4. 7.4.4 BY PATIENT DEMOGRAPHICS, 2025-2035 (USD Billion) |
125. 7.5 Europe MARKET SIZE ESTIMATES; FORECAST | |
  1. 7.5.1 BY TYPE OF TREATMENT, 2025-2035 (USD Billion) | |
  2. 7.5.2 BY MEDICATION CLASS, 2025-2035 (USD Billion) | |
  3. 7.5.3 BY ADMINISTRATION ROUTE, 2025-2035 (USD Billion) | |
  4. 7.5.4 BY PATIENT DEMOGRAPHICS, 2025-2035 (USD Billion) |
126. 7.6 Germany MARKET SIZE ESTIMATES; FORECAST | |
  1. 7.6.1 BY TYPE OF TREATMENT, 2025-2035 (USD Billion) | |
  2. 7.6.2 BY MEDICATION CLASS, 2025-2035 (USD Billion) | |
  3. 7.6.3 BY ADMINISTRATION ROUTE, 2025-2035 (USD Billion) | |
  4. 7.6.4 BY PATIENT DEMOGRAPHICS, 2025-2035 (USD Billion) |
127. 7.7 UK MARKET SIZE ESTIMATES; FORECAST | |
  1. 7.7.1 BY TYPE OF TREATMENT, 2025-2035 (USD Billion) | |
  2. 7.7.2 BY MEDICATION CLASS, 2025-2035 (USD Billion) | |
  3. 7.7.3 BY ADMINISTRATION ROUTE, 2025-2035 (USD Billion) | |
  4. 7.7.4 BY PATIENT DEMOGRAPHICS, 2025-2035 (USD Billion) |
128. 7.8 France MARKET SIZE ESTIMATES; FORECAST | |
  1. 7.8.1 BY TYPE OF TREATMENT, 2025-2035 (USD Billion) | |
  2. 7.8.2 BY MEDICATION CLASS, 2025-2035 (USD Billion) | |
  3. 7.8.3 BY ADMINISTRATION ROUTE, 2025-2035 (USD Billion) | |
  4. 7.8.4 BY PATIENT DEMOGRAPHICS, 2025-2035 (USD Billion) |
129. 7.9 Russia MARKET SIZE ESTIMATES; FORECAST | |
  1. 7.9.1 BY TYPE OF TREATMENT, 2025-2035 (USD Billion) | |
  2. 7.9.2 BY MEDICATION CLASS, 2025-2035 (USD Billion) | |
  3. 7.9.3 BY ADMINISTRATION ROUTE, 2025-2035 (USD Billion) | |
  4. 7.9.4 BY PATIENT DEMOGRAPHICS, 2025-2035 (USD Billion) |
130. 7.10 Italy MARKET SIZE ESTIMATES; FORECAST | |
  1. 7.10.1 BY TYPE OF TREATMENT, 2025-2035 (USD Billion) | |
  2. 7.10.2 BY MEDICATION CLASS, 2025-2035 (USD Billion) | |
  3. 7.10.3 BY ADMINISTRATION ROUTE, 2025-2035 (USD Billion) | |
  4. 7.10.4 BY PATIENT DEMOGRAPHICS, 2025-2035 (USD Billion) |
131. 7.11 Spain MARKET SIZE ESTIMATES; FORECAST | |
  1. 7.11.1 BY TYPE OF TREATMENT, 2025-2035 (USD Billion) | |
  2. 7.11.2 BY MEDICATION CLASS, 2025-2035 (USD Billion) | |
  3. 7.11.3 BY ADMINISTRATION ROUTE, 2025-2035 (USD Billion) | |
  4. 7.11.4 BY PATIENT DEMOGRAPHICS, 2025-2035 (USD Billion) |
132. 7.12 Rest of Europe MARKET SIZE ESTIMATES; FORECAST | |
  1. 7.12.1 BY TYPE OF TREATMENT, 2025-2035 (USD Billion) | |
  2. 7.12.2 BY MEDICATION CLASS, 2025-2035 (USD Billion) | |
  3. 7.12.3 BY ADMINISTRATION ROUTE, 2025-2035 (USD Billion) | |
  4. 7.12.4 BY PATIENT DEMOGRAPHICS, 2025-2035 (USD Billion) |
133. 7.13 APAC MARKET SIZE ESTIMATES; FORECAST | |
  1. 7.13.1 BY TYPE OF TREATMENT, 2025-2035 (USD Billion) | |
  2. 7.13.2 BY MEDICATION CLASS, 2025-2035 (USD Billion) | |
  3. 7.13.3 BY ADMINISTRATION ROUTE, 2025-2035 (USD Billion) | |
  4. 7.13.4 BY PATIENT DEMOGRAPHICS, 2025-2035 (USD Billion) |
134. 7.14 China MARKET SIZE ESTIMATES; FORECAST | |
  1. 7.14.1 BY TYPE OF TREATMENT, 2025-2035 (USD Billion) | |
  2. 7.14.2 BY MEDICATION CLASS, 2025-2035 (USD Billion) | |
  3. 7.14.3 BY ADMINISTRATION ROUTE, 2025-2035 (USD Billion) | |
  4. 7.14.4 BY PATIENT DEMOGRAPHICS, 2025-2035 (USD Billion) |
135. 7.15 India MARKET SIZE ESTIMATES; FORECAST | |
  1. 7.15.1 BY TYPE OF TREATMENT, 2025-2035 (USD Billion) | |
  2. 7.15.2 BY MEDICATION CLASS, 2025-2035 (USD Billion) | |
  3. 7.15.3 BY ADMINISTRATION ROUTE, 2025-2035 (USD Billion) | |
  4. 7.15.4 BY PATIENT DEMOGRAPHICS, 2025-2035 (USD Billion) |
136. 7.16 Japan MARKET SIZE ESTIMATES; FORECAST | |
  1. 7.16.1 BY TYPE OF TREATMENT, 2025-2035 (USD Billion) | |
  2. 7.16.2 BY MEDICATION CLASS, 2025-2035 (USD Billion) | |
  3. 7.16.3 BY ADMINISTRATION ROUTE, 2025-2035 (USD Billion) | |
  4. 7.16.4 BY PATIENT DEMOGRAPHICS, 2025-2035 (USD Billion) |
137. 7.17 South Korea MARKET SIZE ESTIMATES; FORECAST | |
  1. 7.17.1 BY TYPE OF TREATMENT, 2025-2035 (USD Billion) | |
  2. 7.17.2 BY MEDICATION CLASS, 2025-2035 (USD Billion) | |
  3. 7.17.3 BY ADMINISTRATION ROUTE, 2025-2035 (USD Billion) | |
  4. 7.17.4 BY PATIENT DEMOGRAPHICS, 2025-2035 (USD Billion) |
138. 7.18 Malaysia MARKET SIZE ESTIMATES; FORECAST | |
  1. 7.18.1 BY TYPE OF TREATMENT, 2025-2035 (USD Billion) | |
  2. 7.18.2 BY MEDICATION CLASS, 2025-2035 (USD Billion) | |
  3. 7.18.3 BY ADMINISTRATION ROUTE, 2025-2035 (USD Billion) | |
  4. 7.18.4 BY PATIENT DEMOGRAPHICS, 2025-2035 (USD Billion) |
139. 7.19 Thailand MARKET SIZE ESTIMATES; FORECAST | |
  1. 7.19.1 BY TYPE OF TREATMENT, 2025-2035 (USD Billion) | |
  2. 7.19.2 BY MEDICATION CLASS, 2025-2035 (USD Billion) | |
  3. 7.19.3 BY ADMINISTRATION ROUTE, 2025-2035 (USD Billion) | |
  4. 7.19.4 BY PATIENT DEMOGRAPHICS, 2025-2035 (USD Billion) |
140. 7.20 Indonesia MARKET SIZE ESTIMATES; FORECAST | |
  1. 7.20.1 BY TYPE OF TREATMENT, 2025-2035 (USD Billion) | |
  2. 7.20.2 BY MEDICATION CLASS, 2025-2035 (USD Billion) | |
  3. 7.20.3 BY ADMINISTRATION ROUTE, 2025-2035 (USD Billion) | |
  4. 7.20.4 BY PATIENT DEMOGRAPHICS, 2025-2035 (USD Billion) |
141. 7.21 Rest of APAC MARKET SIZE ESTIMATES; FORECAST | |
  1. 7.21.1 BY TYPE OF TREATMENT, 2025-2035 (USD Billion) | |
  2. 7.21.2 BY MEDICATION CLASS, 2025-2035 (USD Billion) | |
  3. 7.21.3 BY ADMINISTRATION ROUTE, 2025-2035 (USD Billion) | |
  4. 7.21.4 BY PATIENT DEMOGRAPHICS, 2025-2035 (USD Billion) |
142. 7.22 South America MARKET SIZE ESTIMATES; FORECAST | |
  1. 7.22.1 BY TYPE OF TREATMENT, 2025-2035 (USD Billion) | |
  2. 7.22.2 BY MEDICATION CLASS, 2025-2035 (USD Billion) | |
  3. 7.22.3 BY ADMINISTRATION ROUTE, 2025-2035 (USD Billion) | |
  4. 7.22.4 BY PATIENT DEMOGRAPHICS, 2025-2035 (USD Billion) |
143. 7.23 Brazil MARKET SIZE ESTIMATES; FORECAST | |
  1. 7.23.1 BY TYPE OF TREATMENT, 2025-2035 (USD Billion) | |
  2. 7.23.2 BY MEDICATION CLASS, 2025-2035 (USD Billion) | |
  3. 7.23.3 BY ADMINISTRATION ROUTE, 2025-2035 (USD Billion) | |
  4. 7.23.4 BY PATIENT DEMOGRAPHICS, 2025-2035 (USD Billion) |
144. 7.24 Mexico MARKET SIZE ESTIMATES; FORECAST | |
  1. 7.24.1 BY TYPE OF TREATMENT, 2025-2035 (USD Billion) | |
  2. 7.24.2 BY MEDICATION CLASS, 2025-2035 (USD Billion) | |
  3. 7.24.3 BY ADMINISTRATION ROUTE, 2025-2035 (USD Billion) | |
  4. 7.24.4 BY PATIENT DEMOGRAPHICS, 2025-2035 (USD Billion) |
145. 7.25 Argentina MARKET SIZE ESTIMATES; FORECAST | |
  1. 7.25.1 BY TYPE OF TREATMENT, 2025-2035 (USD Billion) | |
  2. 7.25.2 BY MEDICATION CLASS, 2025-2035 (USD Billion) | |
  3. 7.25.3 BY ADMINISTRATION ROUTE, 2025-2035 (USD Billion) | |
  4. 7.25.4 BY PATIENT DEMOGRAPHICS, 2025-2035 (USD Billion) |
146. 7.26 Rest of South America MARKET SIZE ESTIMATES; FORECAST | |
  1. 7.26.1 BY TYPE OF TREATMENT, 2025-2035 (USD Billion) | |
  2. 7.26.2 BY MEDICATION CLASS, 2025-2035 (USD Billion) | |
  3. 7.26.3 BY ADMINISTRATION ROUTE, 2025-2035 (USD Billion) | |
  4. 7.26.4 BY PATIENT DEMOGRAPHICS, 2025-2035 (USD Billion) |
147. 7.27 MEA MARKET SIZE ESTIMATES; FORECAST | |
  1. 7.27.1 BY TYPE OF TREATMENT, 2025-2035 (USD Billion) | |
  2. 7.27.2 BY MEDICATION CLASS, 2025-2035 (USD Billion) | |
  3. 7.27.3 BY ADMINISTRATION ROUTE, 2025-2035 (USD Billion) | |
  4. 7.27.4 BY PATIENT DEMOGRAPHICS, 2025-2035 (USD Billion) |
148. 7.28 GCC Countries MARKET SIZE ESTIMATES; FORECAST | |
  1. 7.28.1 BY TYPE OF TREATMENT, 2025-2035 (USD Billion) | |
  2. 7.28.2 BY MEDICATION CLASS, 2025-2035 (USD Billion) | |
  3. 7.28.3 BY ADMINISTRATION ROUTE, 2025-2035 (USD Billion) | |
  4. 7.28.4 BY PATIENT DEMOGRAPHICS, 2025-2035 (USD Billion) |
149. 7.29 South Africa MARKET SIZE ESTIMATES; FORECAST | |
  1. 7.29.1 BY TYPE OF TREATMENT, 2025-2035 (USD Billion) | |
  2. 7.29.2 BY MEDICATION CLASS, 2025-2035 (USD Billion) | |
  3. 7.29.3 BY ADMINISTRATION ROUTE, 2025-2035 (USD Billion) | |
  4. 7.29.4 BY PATIENT DEMOGRAPHICS, 2025-2035 (USD Billion) |
150. 7.30 Rest of MEA MARKET SIZE ESTIMATES; FORECAST | |
  1. 7.30.1 BY TYPE OF TREATMENT, 2025-2035 (USD Billion) | |
  2. 7.30.2 BY MEDICATION CLASS, 2025-2035 (USD Billion) | |
  3. 7.30.3 BY ADMINISTRATION ROUTE, 2025-2035 (USD Billion) | |
  4. 7.30.4 BY PATIENT DEMOGRAPHICS, 2025-2035 (USD Billion) |
151. 7.31 PRODUCT LAUNCH/PRODUCT DEVELOPMENT/APPROVAL | |
  1. 7.31.1 |
152. 7.32 ACQUISITION/PARTNERSHIP | |

Certified Researchers

Customize Report

Postoperative Nausea Vomiting Market Segmentation

Postoperative Nausea Vomiting Market By Type of Treatment (USD Billion, 2025-2035)

Pharmacological Treatment
Non-Pharmacological Treatment
Combination Therapy

Postoperative Nausea Vomiting Market By Medication Class (USD Billion, 2025-2035)

5-HT3 Antagonists
Dopamine Antagonists
Antihistamines
Corticosteroids

Postoperative Nausea Vomiting Market By Administration Route (USD Billion, 2025-2035)

Oral
Intravenous
Rectal

Postoperative Nausea Vomiting Market By Patient Demographics (USD Billion, 2025-2035)

Pediatric Patients
Adult Patients
Geriatric Patients

Certified Researchers

Customize Report

Customer Stories

“This is really good guys. Excellent work on a tight deadline. I will continue to use you going forward and recommend you to others. Nice job”

Noah Malgeri Co-Founder

“Thanks. It’s been a pleasure working with you, please use me as reference with any other Intel employees.”

Joseph Aguayo Sales Operations & Pricing Manager

“Thanks for sending the report it gives us a good global view of the Betaïne market.”

Peter Groot koerkamp Account and Business Manager

“Thank you, this will be very helpful for OQS.”

La Terria Dodd Program Support Specialist

“We found the report very insightful! we found your research firm very helpful. I'm sending this email to secure our future business.”

Younghwan Choi Senior Retail Manager

“I am very pleased with how market segments have been defined in a relevant way for my purposes (such as "Portable Freezers & refrigerators" and "last-mile"). In general the report is well structured. Thanks very much for your efforts.”

Mark Irwin Management Consultant

“I have been reading the first document or the study, ,the Global HVAC and FP market report 2021 till 2026. Must say, good info! I have not gone in depth at all parts, but got a good indication of the data inside!”

Rob Kooiker Group Product Manager HVAC & Fire Protection GMA

“We got the report in time, we really thank you for your support in this process. I also thank to all of your team as they did a great job.”

Akif Moroglu Strategy & Business Development Director

“The Automotive 48V ECU Components Procurement Intelligence Study” was a complex project, but the Market Research Future (MRFR) team handled it with quality, agility, and customer-centricity. They delivered all requested data on time and within the agreed scope. The team, including Shubhendra Anand and Rahul Gotadki, was always readily available to clarify questions and swiftly implement necessary adjustments, driving the project to a successful conclusion within a very demanding timeframe.
I would also like to specifically commend Akshay Agarwal for his responsiveness and support at every stage—from our initial inquiry on May 6th through to final delivery on June 18th. His dedication made the entire process seamless.”

Guilherme Gomes Martins Product Management Director

Case Study

Aerospace & Defense

Future of Dismounted Soldier Systems Market Trends & Adoption Roadmap 2019–2035